Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers say GLP-1 drugs may offer respiratory benefits in addition to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.